Bristol Myers Squibb Loses Supreme Court Challenge to Medicare Price Negotiations

The U.S. Supreme Court rejected a legal challenge from Bristol Myers Squibb against the Medicare drug price negotiation program on May 18, 2026.

This ruling upholds the Inflation Reduction Act policy allowing the federal government to negotiate prices for high-cost prescription drugs.

Bristol Myers Squibb, Novo Nordisk, and Johnson & Johnson argued the law compels manufacturers into government-controlled pricing.

The court’s refusal to hear the case maintains lower court rulings and ensures price negotiations continue as scheduled.